Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2020.567710 http://scihub22266oqcxt.onion/10.3389/fimmu.2020.567710 33178193!7594548!33178193     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Immunol 2020 ; 11 (ä): 567710 Nephropedia Template TP {{tp|p=33178193|t=2020. Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis?|pdf=|usr=}}{{33178193}} gab.com Text Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33178193 #FOAvip The serological responses to both SARS-CoV-1 and SARS-CoV-2 virus have some unique characteristics that suggest cross-reactive priming by other human coronaviruses (hCoVs). The early kinetics and magnitude of these responses are, in some cases, associated with worse clinical outcomes in SARS and COVID-19. Cross-reactive hCoV antibody responses have been detected in both SARS and COVID-19 patients. There is also evidence that pre-existing T cell immunity to common cold coronaviruses can prime the response to SARS-CoV-2. Studies in non-human primates show that SARS-CoV-1 S-protein vaccine-induced antibodies are associated with acute lung injury in macaques challenged with SARS-CoV-1. Here we discuss the potential of cross-reactive immunity to drive the immunopathogenesis of COVID-19 and its implications for current efforts to develop immune-based therapies and vaccines. Twit Text FOAVip Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33178193 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33178193 #FOAvip English Wikipedia <ref>{{Cite pmid|33178193}}</ref> Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis? #MMPMID33178193 Beretta A; Cranage M; Zipeto D Front Immunol 2020[]; 11 (ä): 567710 PMID33178193show ga The serological responses to both SARS-CoV-1 and SARS-CoV-2 virus have some unique characteristics that suggest cross-reactive priming by other human coronaviruses (hCoVs). The early kinetics and magnitude of these responses are, in some cases, associated with worse clinical outcomes in SARS and COVID-19. Cross-reactive hCoV antibody responses have been detected in both SARS and COVID-19 patients. There is also evidence that pre-existing T cell immunity to common cold coronaviruses can prime the response to SARS-CoV-2. Studies in non-human primates show that SARS-CoV-1 S-protein vaccine-induced antibodies are associated with acute lung injury in macaques challenged with SARS-CoV-1. Here we discuss the potential of cross-reactive immunity to drive the immunopathogenesis of COVID-19 and its implications for current efforts to develop immune-based therapies and vaccines. |Animals[MESH] |Antibodies, Viral/*immunology[MESH] |Antibody-Dependent Enhancement[MESH] |CD4-Positive T-Lymphocytes/immunology[MESH] |COVID-19/*immunology/prevention & control/therapy/virology[MESH] |Cross Reactions[MESH] |Humans[MESH] |Immunologic Memory[MESH] |SARS-CoV-2/*immunology[MESH] |Severe Acute Respiratory Syndrome/*immunology/prevention & control/therapy/virology[MESH] |Severe acute respiratory syndrome-related coronavirus/*immunology[MESH]Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis?(epmc).pdf DeepDyve Pubget Overpricing